Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
LUMOS PHARMA, INC. (NLNK) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update",
"Second Quarter 2023 Financial Results"
08/02/2023 144 Form 144 - Report of proposed sale of securities:
06/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lumos Pharma Announces Departure of Chief Medical Officer"
06/02/2023 SC 13D/A Farb Daniel Stuart reports a 6.1% stake in Lumos Pharma, Inc.
05/25/2023 SC 13D/A Farb Daniel Stuart reports a 7.9% stake in Lumos Pharma, Inc.
05/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting"
05/05/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/03/2023 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates",
"First Quarter 2023 Financial Results"
04/03/2023 ARS Form ARS - Annual Report to Security Holders:
03/31/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/31/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/07/2023 10-K Annual Report for the period ended December 31, 2022
03/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology"
03/01/2023 8-K Investor presentation, Quarterly results
Docs: "Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates",
"Full Year 2022 Financial Results"
02/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD"
01/24/2023 SC 13G/A Farb Daniel Stuart reports a 9.1% stake in Lumos Pharma, Inc.
12/12/2022 8-K Quarterly results
11/30/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD"
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/29/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/18/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
04/11/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD"
03/23/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/23/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy